Surging ahead with a dramatic growth in sales, Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of AYUSH has recorded a turnover of Rs. 164.33 crore for FY 2020-21.

This is the highest revenue achieved by the company till date. The company has also recorded an all-time high profit of approximately Rs. 12 crore. In FY 2019-20, the company achieved revenue figures of Rs. 97 crore. This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of COVID-19 pandemic.

The Central Drugs Standards Control Organisation (CDSCO) recently recommended IMPCL's 18 Ayurvedic products for WHO-GMP/COPP certification subject to certain observations in March 2021. This certification is an endorsement of the quality of IMPCL’s products and it will help the company to commence export operation of quality medicines at a global level.

IMPCL is one of the most trusted manufacturers of AYUSH medicines in the country and is known for the authenticity of its formulations.

Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum. It has contributed towards research and development activities and 25 new proprietary Ayurvedic medicines as per the Essential Drug List (EDL).